Current Therapeutic Concepts in Peripartum Cardiomyopathy

J 2015

Current Therapeutic Concepts in Peripartum Cardiomyopathy

KREJČÍ, Jan; Hana POLOCZKOVÁ a Petr NĚMEC

Základní údaje

Originální název

Current Therapeutic Concepts in Peripartum Cardiomyopathy

Autoři

KREJČÍ, Jan; Hana POLOCZKOVÁ a Petr NĚMEC

Vydání

Current Pharmaceutical Design, Sharjah, Bentham Science Publishers, 2015, 1381-6128

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené arabské emiráty

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.052

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00082782

Organizační jednotka

Lékařská fakulta

UT WoS

000349458700010

Klíčová slova anglicky

Peripartum cardiomyopathy; aetiology; diagnosis; treatment

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 2. 2016 16:38, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Peripartum cardiomyopathy (PPCM) is a relatively rare disease characterized by systolic heart failure occuring towards the end of pregnancy or during the months following birth. It is most often seen in women of African descent, and its incidence seems to be slightly increasing in recent years. Other etiologies of heart failure should be excluded to determine the diagnosis of PPCM. The clinical picture corresponds to systolic heart failure. The rapid onset of the symptoms in relation to pregnancy is striking. The essential diagnostic procedures such as echocardiography, cardiac magnetic resonance imaging and endomyocardial biopsy may be beneficial in certain situations. The etiology of the disease remains unclear. Speculated causes include myocarditis, autoimmune disorders, cardiotropic virus infection, and abnormal responses to hemodynamic and hormonal changes during pregnancy. Particular attention is currently given to the concept of increased oxidative stress inducing production of proapoptotic, angiostatic and proinflammatory mediators. Recovery of left ventricular systolic function occurs in about half of the cases. Mortality has been decreasing in recent years, especially in the United States, but is still between 10-15% in less developed countries where therapeutic possibilities are limited. In addition to standard heart failure therapy, specific treatments (pentoxyfilline, bromocriptine, immunomodulatory therapy) have been tested. Mechanical circulatory support is sometimes needed. Heart transplantation is the therapeutic option for the most severe heart failure and is used in about 10% of the cases. Recurrence in subsequent pregnancy is common and therefore, another pregnancy is not recommended in many cases.

Citovat

KREJČÍ, Jan; Hana POLOCZKOVÁ a Petr NĚMEC. Current Therapeutic Concepts in Peripartum Cardiomyopathy. Current Pharmaceutical Design. Sharjah: Bentham Science Publishers, 2015, roč. 21, č. 4, s. 507-514. ISSN 1381-6128.

@article{1298677,
   author = {Krejčí, Jan and Poloczková, Hana and Němec, Petr},
   article_location = {Sharjah},
   article_number = {4},
   keywords = {Peripartum cardiomyopathy; aetiology; diagnosis; treatment},
   language = {eng},
   issn = {1381-6128},
   journal = {Current Pharmaceutical Design},
   title = {Current Therapeutic Concepts in Peripartum Cardiomyopathy},
   volume = {21},
   year = {2015}
}

TY  - JOUR
ID  - 1298677
AU  - Krejčí, Jan - Poloczková, Hana - Němec, Petr
PY  - 2015
TI  - Current Therapeutic Concepts in Peripartum Cardiomyopathy
JF  - Current Pharmaceutical Design
VL  - 21
IS  - 4
SP  - 507-514
EP  - 507-514
PB  - Bentham Science Publishers
SN  - 13816128
KW  - Peripartum cardiomyopathy
KW  - aetiology
KW  - diagnosis
KW  - treatment
N2  - Peripartum cardiomyopathy (PPCM) is a relatively rare disease characterized by systolic heart failure occuring towards the end of pregnancy or during the months following birth. It is most often seen in women of African descent, and its incidence seems to be slightly increasing in recent years. Other etiologies of heart failure should be excluded to determine the diagnosis of PPCM. The clinical picture corresponds to systolic heart failure. The rapid onset of the symptoms in relation to pregnancy is striking. The essential diagnostic procedures such as echocardiography, cardiac magnetic resonance imaging and endomyocardial biopsy may be beneficial in certain situations. The etiology of the disease remains unclear. Speculated causes include myocarditis, autoimmune disorders, cardiotropic virus infection, and abnormal responses to hemodynamic and hormonal changes during pregnancy. Particular attention is currently given to the concept of increased oxidative stress inducing production of proapoptotic, angiostatic and proinflammatory mediators. Recovery of left ventricular systolic function occurs in about half of the cases. Mortality has been decreasing in recent years, especially in the United States, but is still between 10-15% in less developed countries where therapeutic possibilities are limited. In addition to standard heart failure therapy, specific treatments (pentoxyfilline, bromocriptine, immunomodulatory therapy) have been tested. Mechanical circulatory support is sometimes needed. Heart transplantation is the therapeutic option for the most severe heart failure and is used in about 10% of the cases. Recurrence in subsequent pregnancy is common and therefore, another pregnancy is not recommended in many cases.
ER  -

KREJČÍ, Jan; Hana POLOCZKOVÁ a Petr NĚMEC. Current Therapeutic Concepts in Peripartum Cardiomyopathy. \textit{Current Pharmaceutical Design}. Sharjah: Bentham Science Publishers, 2015, roč.~21, č.~4, s.~507-514. ISSN~1381-6128.

Přehled o publikaci